Dr. Mudhasir Ahmad
Dr. Mudhasir Ahmad Sr. Consultant, Department of Medical Oncology

MD Medicine, DNB Medical Oncology, ESMO Medical Oncology

Qualification
Education
  • DNB Medical Oncology
  • ECMO(European Certification)
  • M.D. Internal Medicine
  • M.B.B.S
Membership
  • ASCO – American society of medical oncology (August-2013 till present)
  • ESMO – European society of Medical Oncology (May-2013 till present)
  • MOF – Medical oncologists federation of A P, India (May-2013 till present)
  • IASLC - International Association for the Study of Lung Cancer (2015 and 2016)
  • ISMPO - Indian society of medical and paediatric oncology
  • Delhi Oncology Forum
Awards & Scholarships
  • Indian Council of medical research (ICMR) grant for research presentation in 13th World gastrointestinal cancer congress, Barcelona, Spain, July, 2013.
  • European Society of Medical Oncology certification (ESMO)
  • Immuno Oncology Preceptorship, European society of Medical Oncology, in Prague, European Union.
  • Lung Cancer Preceptorship, European Society of Medical Oncology, Singapore
  • Uro Oncology Renal Cell Carcinoma Preceptorship, Taiwan Veterans Hospital, Taipei
Experience & Areas of Interest
Experience
  • Senior Consultant Medical Oncology at Jaypee Hospital, Noida
  • Consultant Medical oncologist International Oncology at Fortis Hospital Noida and Faridabad, NCR, India.
  • Consultant Medical oncologist Healthcare global (HCG) Cancer hospital, New Delhi/NCR (Shanti Mukund Hospital)
  • Junior consultant (initially Senior Registrar) Medical oncologist in the department of Medical Oncology/Hematology/BMT, Apollo Hospital Jublee Hills, Hyderabad
Areas Of Interest
  • Immunotherapy
  • Targeted therapy and genetic mutation based therapy
  • cancers of breast, gynecological (ovarian, cervix, uterine), lung, gastrointestinal, head and neck, lymphomas, myeloma, etc.
Publications
  • Hospital based observational study on the tolerability, and efficacy of two Gemcitabine Oxaliplatin regimens Abstract. Annals of Oncology 24 (4): iv38–iv121, 2013
  • Hypercvad+Bortezomib Is a Well Tolerated Salvage Regimen for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia. Blood (ASH- American Society of hematology- Annual Meeting Abstracts) 2010 116: Abstract 4345.
  • High Sensitivity C- Reactive Protein in the Male Patients with Angina with Normal Coronary Arteries. IJHSR. 2014; 4(4): 69-79
  • An Unusual Case of Refractory Seizure Disorder; An Insight into the Cause of Delayed Presentation of Functional Insulinoma. Austral - Asian Journal of Cancer ISSN-0972-2556, Vol. 13, No. 2, April 2014
  • Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma while on sunitinib. Published in Indian Journal of cancer in Jan-Mar, 2016 and as poster presentation in 31st ICON CONFERENCE Bhopal, MP, India. September 12, 2014. DOI: 10.4103/0019-509X.180852
  • Posterior reversible encephalopathy syndrome, the most uncommon adverse effect of one the commonest chemotherapy regimens, FOLFOX. Apollo Medicine March 2015. Published by Elsevier. Apollo medicine 12 (2015) 54-5 6
  • Infections in Hematopoietic Stem Cell Transplantation Recipients in the Pre-Engraftment Period. Global Journal of Hematology and Blood Transfusion, 09 January 2015. ISSN (online): 2408-9877
  • Urinary bladder Involvement in Mycosis Fungoides without Sezary Syndrome, a Rare Presentation. As a poster at Apollo Cancer Conclave and Cancer International. February 2015
  • Extrarenal Rhabdoid Tumor of Perineum – a rare case presentation. As a poster at Apollo Cancer Conclave and Cancer International. February 2015
Phone Number: +911204122222